Treatment modalities of regorafenib and survival in metastatic colorectal (mCRC) patients: A real-world multicenter retrospective study.

Wang Qu(Chinese Academy of Medical Sciences & Peking Union Medical College), Aiping Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Hao Yan, Yongkun Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Aimin Zang, Zhichao Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiujuan Qu(First Hospital of China Medical University), Bo Liu(Union Hospital), Yunbo Zhao(University of Science and Technology of China), Xiaobing Chen(Chinese Academy of Sciences), Liangjun Zhu, Shengmian Li(Hebei Medical University), Zimin Liu(Qingdao University)
Journal of Clinical Oncology
June 1, 2023
10.1200/jco.2023.41.16_suppl.e15571
Cited by 1

Related Papers

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
|The Lancet Respiratory Medicine|2022|235
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
|癌症：英文版|2021|207